Wegovy® (semaglutide 2.4mg) by Novo Nordisk is now Available in Singapore for Weight Management
Wegovy® (semaglutide 2.4mg) is a once-weekly injectable treatment indicated for chronic weight management in adults and adolescents (aged 12 and above) living with obesity (BMI ≥30 kg/m²), or who are overweight (BMI ≥27 kg/m² to <30 kg/m²) with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia1. It is used alongside a reduced-calorie diet and increased physical activity, supporting Singapore's efforts to improve population health.
The treatment works by addressing one of the underlying biological drivers of obesity. Wegovy® (semaglutide 2.4mg) is a GLP-1 receptor agonist with 94% similarity to the body's natural GLP-1 hormone. It activates receptors involved in appetite regulation, helping individuals feel full sooner and reduce food intake1. This mechanism supports weight loss when combined with sustainable lifestyle changes.
The availability of Wegovy® (semaglutide 2.4mg) comes as obesity continues to pose a significant health burden in Singapore. An estimated 600,000 adults are currently living with obesity2-4, a condition associated with more than 200 health complications5. Despite its prevalence and medical complexity, obesity remains heavily stigmatised—often misunderstood as merely the result of poor personal choices. Individuals living with obesity frequently face discrimination and mental health challenges which further isolate them. This misplaced blame, rather than targeting the disease itself, creates barriers to and slows the advancement of effective obesity treatment. Recognised by World Health Organization as a chronic disease6, obesity requires compassionate evidence-based care. The launch of Wegovy® (semaglutide 2.4mg) in Singapore provides a new treatment option for weight management available through private prescription.
Dr Abel Soh, Abel Soh Diabetes, Thyroid and Endocrine Clinic and Chairperson for Endocrine and Metabolic Society of Singapore (EMSS) stated, 'Obesity is not simply the result of lifestyle choices — it is a medically recognised chronic disease influenced by a complex interplay of genetics, hormones, and environment. In my clinical practice, I see firsthand how many individuals blame themselves when in fact, their biology is often working against them. It's time we shift the conversation from blame to support in the management of individuals with obesity'
Lifestyle factors in Singapore further contribute to the challenge. In Singapore's demanding work culture—where full-time employees work an average of 44.6 hours per week7, with time constraints and fatigue frequently cited as barriers to maintaining regular physical activity. These circumstances underscore the importance of comprehensive treatment strategies that facilitate the adoption of healthier lifestyles, including increased physical activity and a reduced-calorie diet, as integral components of long-term weight management.
Mr Vincent Siow, General Manager, Novo Nordisk Singapore, said 'With treatments like Wegovy® (semaglutide 2.4mg) now available in Singapore, we have an opportunity to provide healthcare professionals with more evidence-based options to support their patients in regaining control of their health and improving long-term outcomes.'
References: Wegovy Singapore Prescribing Information, February 2025Cuciureanu M, Caratașu CC, Gabrielian L, Frăsinariu OE, Checheriță LE, Trandafir LM, Stanciu GD, Szilagyi A, Pogonea I, Bordeianu G, Soroceanu RP, Andrițoiu CV, Anghel MM, Munteanu D, Cernescu IT, Tamba BI. 360-Degree Perspectives on Obesity. Medicina (Kaunas). 2023 Jun 9;59(6):1119. doi: 10.3390/medicina59061119. PMID: 37374323; PMCID: PMC10304508.World Obesity. Retrieved from https://www.worldobesity.org/about/about-obesity/prevalence-of-obesity World Obesity. Retrieved from https://data.worldobesity.org/country/singapore-192/Scott I. Kahan, MD, MPH. Practical Strategies for Engaging Individuals With Obesity in Primary Care. Mayo Clin Proc. 2018;93(3):351-359 2. CDC, Cancers Associated with Overweight and Obesity Makeup 40 percent of Cancers Diagnosed in the United States. Available at https://www.cdc.gov/media/releases/2017/p1003-vs-cancer-obesity.html.World Health Organization. (2024). Obesity and overweight.WHO.https://www.who.int/news-room/factsheets/detail/obesity-and-overweight As accessed on 22nd May 2025.Leu J, Rebello SA, Sargent GM, Kelly M, Banwell C. Hard work, long hours, and Singaporean young adults' health. A qualitative study. Frontiers in Public Health. 2023; 11. https://doi.org/10.3389/fpubh.2023.1082581
Hashtag: #NovoNordisk #Wegovy
The issuer is solely responsible for the content of this announcement.
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs around 77,400 people in 80 countries and markets its products in around 170 countries. In Singapore, Novo Nordisk has been present since 1997 and has approximately 100 employees.
For more information, visit novonordisk.sg.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Researchers make disturbing discovery about health risks lurking in common products: 'Highlights the critical need for further exploration'
A new study may help to unpack possible effects of microplastic pollution, including from biodegradable alternatives, on metabolism and gut bacteria. The findings suggest some concerning signs that demand further exploration into long-term health risks that could be linked to microplastic exposure and ingestion, such as the potential for gut inflammation and microbiome disruption. Polylactic acid, or PLA, is a bioplastic commonly marketed as biodegradable or compostable, and it's often used in food packaging. Made from fermented plant starch rather than fossil fuels, when broken down under the right conditions, it can degrade into lactic acid, generally understood as safe. However, PLA can also break down incompletely, resulting in some divided opinions on the material and its potential health and environmental advantages over traditional plastics. Researchers from China say their new findings indicate that PLA microplastics can break down into nanoparticles inside the body and potentially trigger a range of harmful biological responses. In their study, published in June online by the Journal of Hazardous Materials, mice were orally exposed to a daily dose of PLA microplastics. Researchers noted that "the particles retrieved from mouse feces exhibited a significant size reduction, breaking down from the micrometer scale to the nanometer scale." Short-term oral exposure appeared to impact gut microbiota and induce inflammation, while longer-term exposure seemed to cause persistent changes, including to the metabolism. The co-authors of this new study say the research "highlights the critical need for further exploration into the long-term health risks of microplastic exposure," even when it comes to materials manufactured to be biodegradable or compostable. While microplastic pollution has been studied in marine animals and environments, as well as the occasional tortoise or donkey, this study focuses on the potential for serious risks to human health and looks at PLA microplastics in particular. In 2019, a research team, with support from the World Wide Fund, estimated that people may consume up to 5 grams of microplastics per week — roughly the weight of a credit card. Some studies have also investigated possible links between microplastic exposure and chronic illnesses, such as endometriosis, though these studies have largely looked at traditional plastics. When PLA microplastics are used, it tends to be because of their eco-friendly image as a biodegradable alternative to traditional plastic types. Leveraging safe, sustainable alternatives to fossil fuel-based products is critical, but this study shows that bioplastics may still pose health threats inside the body, meriting further investigation. The researchers suggest that nanoparticles resulting from PLA breakdown could disrupt gut bacteria and contribute to inflammation, which has been linked to a range of illnesses from liver disease to neurodegenerative disorders. While more research is needed to provide a complete and thorough understanding of the potential impacts of microplastics — including from bioplastics — on our well-being, this study points toward the possibility that reducing their use could come with some health benefits. As more experts are suggesting, while we don't yet have a full picture of microplastic hazards, we may have enough information to warrant making some changes now. Do you worry about air pollution in and around your home? Yes — always Yes — often Yes — sometimes No — never Click your choice to see results and speak your mind. Steps like cutting back on single-use plastic cutlery and straws at restaurants, opting for non-plastic reusable containers and shopping bags, and minimizing plastic-packaged food may help reduce personal exposure and the amount of plastic waste in the world. On a broader level, stronger regulations, corporate accountability, and funding for more research are all critical to curbing plastic pollution and protecting public health. Encouragingly, studies like this are pushing the conversation forward, showing that biodegradable may not always mean completely harmless. Join our free newsletter for good news and useful tips, and don't miss this cool list of easy ways to help yourself while helping the planet.
Yahoo
4 hours ago
- Yahoo
Trump's attorney general drops fraud case tied to COVID vaccinations
WASHINGTON (Reuters) -U.S. Attorney General Pam Bondi on Saturday dropped a case against a Utah doctor accused of falsifying COVID-19 vaccination certificates and destroying more than $28,000 worth of government-provided COVID-19 vaccines. Bondi, in a statement posted on X, said Michael Kirk Moore Jr., of Salt Lake County, Utah did not deserve the jail time he was facing. Moore was indicted by a federal grand jury in 2023 and his trial had begun earlier this month. "Dr. Moore gave his patients a choice when the federal government refused to do so. He did not deserve the years in prison he was facing. It ends today," Bondi said. COVID-19 vaccine skeptics have been embraced by the Trump administration. The Pentagon, for example, has sought to re-enlist servicemembers who were ousted for refusing to be vaccinated during the pandemic. Health Secretary Robert F. Kennedy Jr., who for decades has sown doubt about the safety of vaccines contrary to evidence and research by scientists, wrote on X in April: "Dr. Moore deserves a medal for his courage and his commitment to healing!" According to a 2023 statement from the U.S. Attorney's Office in Utah, Moore allegedly ran the false certifications out of a plastic surgery center. His activities allegedly included administering saline shots to minors, at the request of their parents, so the children would think they were receiving COVID-19 vaccines, the statement said. Marjorie Taylor Greene, a U.S. lawmaker from Georgia and staunch Trump supporter, had championed dropping the case against Moore, who she called a hero in a statement on Saturday. "We can never again allow our government to turn tyrannical under our watch," she said in a post on X. The latest move by Bondi comes amid scrutiny of her firings of senior Justice Department officials who worked on investigations into Trump, stoking accusations of political retribution in a department whose mission is to enforce U.S. laws.
Yahoo
4 hours ago
- Yahoo
UnitedHealth Group Incorporated (UNH): 'Medicare Fraud Is Prison,' Warns Jim Cramer
We recently published . UnitedHealth Group Incorporated (NYSE:UNH) is one of the stocks Jim Cramer recently discussed. UnitedHealth Group Incorporated (NYSE:UNH) is the largest healthcare benefits provider in America. It is also one of the worst-performing stocks in 2025 as the shares have lost 40% year-to-date. UnitedHealth Group Incorporated (NYSE:UNH)'s shares sank by a massive 27.3% in April after the firm stunned investors by missing analyst estimates for its latest quarter. Cramer's recent remarks about the firm discussed media reports of impropriety and pointed out that UnitedHealth Group Incorporated (NYSE:UNH) wouldn't be buying shares if they were true. However, this time, he had a much darker tone: '[On a WSJ report that UNH deploys doctors and nurses to gather diagnoses that bolster its payments with UNH responding that it welcomes reviews] Well I'm glad they welcome it but I do want to caution them, and I think I happen to like this CEO very much, but Medicare fraud is prison. It's not, hey listen we'll slap UNH on the wrist. It's prison. And it's probably the most I think easily, the crimes are easily followed and the judgement is swift. The reason why people are so focused on this is that it's not a fine.' Previously, the CNBC host discussed UnitedHealth Group Incorporated (NYSE:UNH) in detail: 'The third worst performer was, wow, UnitedHealth Group, suddenly very troubled managed care company that used to be the ultimate darling in the group. It's down 38% in the first half. UnitedHealth's troubles are very well documented. I'm not even talking about the assassination last December, as terrible as that was. The real trouble started in April when the company reported a weak quarter, dragged down by high utilization rates, meaning people are getting much more healthcare than UNH… needs to pay for. A senior healthcare professional giving advice to a patient in a clinic. What's starting to become clear is that the company made some major missteps with its underwriting, especially with Medicare Advantage plans for seniors. They're far from the only one in the industry with this problem, but UNH might be the hardest hit. This is the largest player in the Medicare Advantage space with the most extensive data, and they really should have been able to avoid these mistakes. They almost always have, but clearly, they didn't. The company made a change in the top mid-May with CEO Andrew Witty stepping down for personal reasons. Turning around UNH is now the job of Stephen Hemsley, whom I really like. He was previously CEO from 2006 to 2017. And there's some nascent optimism that he can get this business back on track, but I don't necessarily think this will happen quickly. If you're inclined to bet on a UNH comeback, I suggest that you take it slowly because you got all the time in the world. You actually might even want to wait to see the next quarter, which could be what we call a clearing event for the negatives.' While we acknowledge the potential of UNH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
